All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Loncastuximab tesirine plus rituximab in patients with R/R FL
|
Patients with R/R FL may have rapid disease progression, characterized by increasingly treatment-refractory disease and shorter intervals to next therapy. There remains an unmet need for fixed-duration novel agents that can achieve high response rates and durable efficacy whilst maintaining acceptable safety profiles.1 A single arm phase II trial (NCT04998669) conducted at the Sylvester Comprehensive Cancer Center, US, evaluated the efficacy and safety of loncastuximab tesirine plus rituximab in patients with R/R FL (N = 39).1 Patients who had progressed after ≥2 lines of systemic therapy and presenting with progression or relapse within 24 months (POD24) after 1L treatment, ≥1 GELF criteria, or second relapse, had measurable disease according to Lugano 2014 classification, and ECOG PS 0–2 were included. The primary endpoint was CR at Week 12 assessed by the Lugano 2014 classification, with a secondary endpoint of Week 12 ORR. Results were published in Lancet Haematology by Alderuccio et al.1 |
| Key learnings |
| The CR rate was 67% at Week 12, rising to 77% at Week 21. The ORR was 97%. Response rates were high across high-risk subgroups, including POD24, high FLIPI scores, and GELF criteria, with CR rates of 85%, 67%, and 75% in these subgroups, respectively. |
| The 12-month PFS and OS rates were 94.6% and 94.1%, respectively, with median PFS and OS rates not yet reached. |
| The most common Grade ≥3 TEAEs were lymphopenia (21%) and neutropenia (13%). No fatal TEAEs occurred. |
| Loncastuximab tesirine + rituximab demonstrated clinically meaningful activity in R/R FL, including high response rates in difficult-to-treat groups, with manageable safety. A fixed-duration and ambulatory regimen of loncastuximab tesirine + rituximab offers a promising combination in the 2L and later treatment of FL. |
Abbreviations: 1L, first-line; 2L, second-line; CR, complete response; ECOG PS, Eastern Cooperative Oncology Group Performance Status; GELF, Groupe d’Etude des Lymphomes Folliculaires; FLIPI, Follicular Lymphoma International Prognostic Index; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; POD24, progression or relapse within 24 months; R/R, relapsed/refractory; TEAE, treatment-emergent adverse event.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
What is your preferred therapy class when planning treatment for a patient with R/R DLBCL after 2 or more lines of systemic therapy ?
